$1.33 -0.01 (-0.75%) Arqule Inc - NASDAQ

Dec. 9, 2016 | 04:00 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 1.33
Trade Time: Dec 09 04:00 PM Eastern Daylight Time
Change: -0.01 (-0.75%)
Prev Close: 1.34
Open: 1.39
Bid: 1.32
Ask: 1.33
  1. No results found.
  1. Benzinga's Top Upgrades

    Benzinga | Dec. 21, 2015 | 09:53AM EST
  2. ArQule Presents Results From Phase 1b Expansion Study of ARQ 092 at the 2015 European Cancer Conference

    Benzinga | Sep. 28, 2015 | 06:33AM EST
  3. ArQule Presents Additional Clinical Biomarker Data From Phase 2 Study of Tivantinib in Hepatocellular Carcinoma at International Liver Cancer Association Conference

    Benzinga | Sep. 8, 2015 | 06:30AM EST
  4. Jean-Marie Eveillard Adds to Stake in Arqule Inc.

    GuruFocus | May. 3, 2015 | 23:59PM EST
  5. Morning Market Movers

    Benzinga | Nov. 10, 2014 | 09:43AM EST
  6. Stocks Hitting 52-Week Lows

    Benzinga | Apr. 14, 2014 | 09:30AM EST
  7. Earnings Scheduled For March 5, 2014

    Benzinga | Mar. 5, 2014 | 04:41AM EST
  8. Benzinga's Top #PreMarket Gainers

    Benzinga | Jan. 17, 2014 | 08:10AM EST
  9. Benzinga's Top Pre-Market Gainers

    Benzinga | Sep. 27, 2013 | 07:09AM EST
  10. UPDATE: Citigroup Downgrades ArQule on Increased Uncertainty Around Lead Cancer Drug Candidate

    Benzinga | Sep. 18, 2013 | 10:06AM EST
  11. Morning Market Losers

    Benzinga | Sep. 3, 2013 | 08:57AM EST
  12. Daiichi Sankyo and ArQule Announce Phase 2 Trial with Tivantinib in Colorectal Cancer Did Not Meet Primary Endpoint

    Benzinga | Jan. 11, 2013 | 00:32AM EST
  13. ArQule Inc. Reports Operating Results (10-Q)

    GuruFocus | Nov. 1, 2012 | 09:02AM EST
  14. Stocks Hitting 52-Week Lows

    Benzinga | Oct. 2, 2012 | 03:53AM EST
  15. Morning Market Losers

    Benzinga | Oct. 2, 2012 | 03:16AM EST
Trading Center